Nakamura Haruhiko, Ando Koji, Shinmyo Takuo, Morita Katsuhiko, Mochizuki Atsushi, Kurimoto Noriaki, Tatsunami Shinobu
Departments of Chest Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Ann Thorac Cardiovasc Surg. 2011;17(5):469-80. doi: 10.5761/atcs.oa.10.01637. Epub 2011 Jul 27.
It is not clear whether women with non-small-cell lung cancer (NSCLC) live significantly longer than men. Thus, we conducted a meta-analysis of published studies to quantitatively compare NSCLC survival data between genders.
A MEDLINE Web search for computer-archived bibliographic data regarding overall survival differences between genders was performed. DerSimonian-Laird random effects analysis was used to estimate the pooled hazard ratio (HR).
We selected 39 articles as appropriate data sources, involving 86 800 patients including 32 701 women and 54 099 men. Combined HRs for women vs. men in studies using univariate and multivariate analyses respectively were 0.79 (p <0.0001) and 0.78 (p <0.0001). Pooled HRs for 3 study subgroups having (1) fewer than 30% stage I cases, (2) fewer than 50% adenocarcinoma cases, and (3) statistical adjustment for smoking status all indicated the survival advantage of women.
This meta-analysis of published data concerning NSCLC patients indicated significantly better survival for women.
非小细胞肺癌（NSCLC）女性患者的生存期是否显著长于男性尚不清楚。因此，我们对已发表的研究进行了荟萃分析，以定量比较不同性别的NSCLC生存数据。
通过医学在线数据库（MEDLINE）网络搜索关于性别间总生存差异的计算机存档书目数据。采用DerSimonian-Laird随机效应分析来估计合并风险比（HR）。
我们选择了39篇文章作为合适的数据源，涉及86800例患者，其中包括32701例女性和54099例男性。在分别使用单变量和多变量分析的研究中，女性与男性的合并HR分别为0.79（p<0.0001）和0.78（p<0.0001）。在3个研究亚组中，即（1）I期病例少于30%、（2）腺癌病例少于50%、（3）对吸烟状况进行统计调整的亚组，合并HR均显示女性具有生存优势。
这项对已发表的NSCLC患者数据的荟萃分析表明，女性的生存期明显更好。
